Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.00.

VYGR has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 18th.

Voyager Therapeutics Trading Down 1.4 %

Shares of NASDAQ VYGR opened at $5.67 on Friday. The firm’s 50-day moving average price is $6.53 and its 200-day moving average price is $7.36. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72. The firm has a market capitalization of $309.73 million, a P/E ratio of 7.99 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the business earned ($0.59) earnings per share. Equities research analysts forecast that Voyager Therapeutics will post -1.03 EPS for the current year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VYGR. Great Point Partners LLC bought a new position in shares of Voyager Therapeutics during the 2nd quarter valued at approximately $12,668,000. Erste Asset Management GmbH bought a new position in Voyager Therapeutics in the 3rd quarter worth approximately $6,192,000. Farallon Capital Management LLC boosted its holdings in Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after buying an additional 1,000,000 shares during the period. Vanguard Group Inc. boosted its holdings in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after buying an additional 702,030 shares during the period. Finally, Armistice Capital LLC boosted its holdings in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares during the period. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.